Literature DB >> 10760785

Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells.

G Eberl1, H R MacDonald.   

Abstract

NK T cells produce cytokines when their semi-invariant TCR engages glycolipids associated with CD1d. The physiological consequences of NKT cell activation remain controversial, although they have been implicated in control of autoimmunity, parasites and tumors. We show here that specific activation of NKT cells in liver and spleen leads to a rapid induction of extensive NK cell proliferation and cytotoxicity. This NK cell activation is dependent, at least in part, on IFN-gamma production by NKT cells and IL-12 production by antigen-presenting cells. Remarkably, activation of NK cells by NKT cells is highly selective, since bystander T and B lymphocytes show transient expression of activation markers but almost no proliferation. Collectively our data suggest that CD1d-dependent NKT cells regulate innate immunity by sampling blood-borne glycolipid antigens and rapidly activating NK cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10760785     DOI: 10.1002/(SICI)1521-4141(200004)30:4<985::AID-IMMU985>3.0.CO;2-E

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  114 in total

1.  Slam haplotypes modulate the response to lipopolysaccharide in vivo through control of NKT cell number and function.

Authors:  Idil Aktan; Alan Chant; Zachary D Borg; David E Damby; Paige C Leenstra; Graham W J Lilley; Graham W G Lilley; Joseph Petty; Benjamin T Suratt; Cory Teuscher; Edward K Wakeland; Matthew E Poynter; Jonathan E Boyson
Journal:  J Immunol       Date:  2010-06-07       Impact factor: 5.422

Review 2.  Innate self recognition by an invariant, rearranged T-cell receptor and its immune consequences.

Authors:  Aleksandar K Stanic; Jang-June Park; Sebastian Joyce
Journal:  Immunology       Date:  2003-06       Impact factor: 7.397

3.  The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion.

Authors:  Michael T Wilson; Cecilia Johansson; Danyvid Olivares-Villagómez; Avneesh K Singh; Aleksandar K Stanic; Chyung-Ru Wang; Sebastian Joyce; Mary Jo Wick; Luc Van Kaer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

Review 4.  Regulation of immune responses by CD1d-restricted natural killer T cells.

Authors:  Luc Van Kaer
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

5.  α-Galactosylceramide protects mice from lethal Coxsackievirus B3 infection and subsequent myocarditis.

Authors:  C Y Wu; Y Feng; G C Qian; J H Wu; J Luo; Y Wang; G J Chen; X K Guo; Z J Wang
Journal:  Clin Exp Immunol       Date:  2010-08-19       Impact factor: 4.330

6.  Alpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection.

Authors:  Isabel Sada-Ovalle; Markus Sköld; Tian Tian; Gurdyal S Besra; Samuel M Behar
Journal:  Am J Respir Crit Care Med       Date:  2010-05-27       Impact factor: 21.405

7.  Engagement of glycosylphosphatidylinositol-anchored proteins results in enhanced mouse and human invariant natural killer T cell responses.

Authors:  Lisa A Mannik; Ian Chin-Yee; Shayan Sharif; Luc Van Kaer; Terry L Delovitch; S M Mansour Haeryfar
Journal:  Immunology       Date:  2010-11-11       Impact factor: 7.397

Review 8.  NKT cell immune responses to viral infection.

Authors:  Marlowe S Tessmer; Ayesha Fatima; Christophe Paget; Francois Trottein; Laurent Brossay
Journal:  Expert Opin Ther Targets       Date:  2009-02       Impact factor: 6.902

9.  Selective loss of natural killer T cells by apoptosis following infection with lymphocytic choriomeningitis virus.

Authors:  J A Hobbs; S Cho; T J Roberts; V Sriram; J Zhang; M Xu; R R Brutkiewicz
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Antigen-dependent versus -independent activation of invariant NKT cells during infection.

Authors:  Keli L Holzapfel; Aaron J Tyznik; Mitchell Kronenberg; Kristin A Hogquist
Journal:  J Immunol       Date:  2014-05-09       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.